[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351067-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-351067-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","circulating-tumor-dna-informs-clinical-practice-in-patients-with-recurrentmetastatic-gastroesophageal-cancers","Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers","","Circulating tumor DNA (ctDNA) is evaluated as a biomarker for treatment response and molecular residual disease in recurrent or metastatic gastroesophageal cancers. A multi-institutional retrospective analysis assessed ctDNA using a personalized, tumor-informed assay (Signatera) in 200 patients, correlating longitudinal ctDNA dynamics with clinical and radiographic findings. Results show that sustained ctDNA negativity during treatment predicts benefit, while conversion to ctDNA positivity signals progression; ctDNA clearance relates to favorable outcomes.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-tumor-dna-informs-clinical-practice-in-patients-with-recurrentmetastatic-gastroesophageal-cancers/351067/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-informs-clinical-practice-in-patients-with-recurrentmetastatic-gastroesophageal-cancers/351067.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the clinical purpose of using circulating tumor DNA (ctDNA) in recurrent/metastatic gastroesophageal cancers?","Question",{"text":62,"@type":63},"ctDNA is used to assess treatment response and molecular residual disease, and to infer progression risk based on ctDNA dynamics over time.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was ctDNA testing performed in the study?",{"text":67,"@type":63},"Patients underwent commercial ctDNA testing with a personalized, tumor-informed assay (Signatera; Natera, Inc.).",{"name":69,"@type":60,"acceptedAnswer":70},"What ctDNA patterns during treatment were most associated with outcomes?",{"text":71,"@type":63},"Patients who remained ctDNA-negative throughout treatment showed treatment benefit, while those who converted to ctDNA positivity progressed; ctDNA clearance was linked to favorable outcomes.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},351067,1790165325,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10. 1002/cncr.70242  \nORIGINAL ARTICLE  \nCirculating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers  \nRutika Mehta MD, MPH1 | Samuel Rivero-Hinojosa PhD2 |  \nFarshid Dayyani MD, PhD3  | Jenifer Ferguson PhD2 | Bushra Shariff DO4 | Vasily N. Aushev PhD2 | Griffin L. Budde PharmD2 | J. Bryce Ortiz PhD2  | Giby V. George MD2 | Shruti Sharma PhD2 | Adham A. Jurdi MD2  | Minetta C. Liu MD2 | Ronald L. Drengler MD5 | Samuel J. Klempner MD6  \n1Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA  \n2Natera, Inc., Austin, Texas, USA  \n3Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA  \n4Department of Internal Medicine, H. Lee Moffitt Cancer Center, Tampa, Florida, USA 5Medical Oncology, The START Center for Cancer Care, San Antonio, Texas, USA 6Massachusetts General Hospital, Boston, Massachusetts, USA  \nCorrespondence  \nRutika Mehta, Division of Hematology/ Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY 10021, USA. Email: [rum9028@med.cornell.edu](rum9028@med.cornell.edu)  \nFunding information  \nNatera Inc.  \nAbstract  \nBackground: Circulating tumor DNA (ctDNA) is a valuable biomarker for assessing treatment response and molecular residual disease. In advanced esophageal and gastric cancer (gastroesophageal cancer [EGC]), ctDNA dynamics remain poorly understood. The authors investigated ctDNA in patients with advanced EGC to evaluate its clinical utility.  \nMethods: This was a multi-institutional, retrospective analysis of 200 patients with recurrent/metastatic EGCs who underwent commercial ctDNA testing using a personalized, tumor-informed assay (Signatera; Natera, Inc.). Patients were divided into cohort A (N = 36; stage I–III with recurrence) or cohort B (N = 164; metastatic at diagnosis). Longitudinal ctDNA dynamics were correlated with clinical and radiographic findings.  \nResults: In cohort A, 31 of 36 patients (86. 1%) had ctDNA collected ≤90 days before recurrence; of these, 25 of 31 patients (80.65%) were ctDNA-positive before recurrence. In cohort B, baseline ctDNA was available for 29 of 164 patients (17.68%), and all 29 were ctDNA-positive. Among 52 patients who had ontreatment ctDNA assessments, 62 treatment lines were analyzed (N = 6 in cohort A; N = 46 in cohort B). All who remained ctDNA-negative throughout treatment (Neg-Neg) showed treatment benefit (n = 6 of 6). Those who converted to ctDNApositive (Neg-Pos) progressed (n = 2 of 2). Among ctDNA-positive patients (PosPos), 27 of 40 (67.5%) showed treatment benefit, whereas 13 of 40 (32.5%) progressed. Patients who cleared ctDNA (Pos-Neg) had favorable outcomes (12 of 14 patients; 85. 7%). A decrease >90% in ctDNA levels among Pos-Pos patients was linked to superior progression-fee survival. Grouping treatment lines into favorable (Neg-Neg, Pos-Neg, and Pos-Pos with >90% decrease) versus unfavorable (Neg-Pos  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70242.  \n[https://doi.org/10.1002/cncr.70242](https://doi.org/10.1002/cncr.70242)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 9  \nand Pos-Pos with a \u003C90% decrease or an increase) had significantly improved progression-free survival in the favorable group (p \u003C .0001).  \nConclusions: ctDNA dynamics predicted progression and may guide treatment or imaging. ctDNA offers a minimally invasive, cost-effective adjunct to radiographic surveillance.  \nKEYWORDS  \ncirculating tumor DNA (ctDNA), ctDNA dynamics, metastatic ","cbCaierObviEbmD6","https://ap.wps.com/l/cbCaierObviEbmD6","pdf",537297,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the clinical purpose of using circulating tumor DNA (ctDNA) in recurrent/metastatic gastroesophageal cancers?\",\"answer\":\"ctDNA is used to assess treatment response and molecular residual disease, and to infer progression risk based on ctDNA dynamics over time.\"},{\"question\":\"How was ctDNA testing performed in the study?\",\"answer\":\"Patients underwent commercial ctDNA testing with a personalized, tumor-informed assay (Signatera; Natera, Inc.).\"},{\"question\":\"What ctDNA patterns during treatment were most associated with outcomes?\",\"answer\":\"Patients who remained ctDNA-negative throughout treatment showed treatment benefit, while those who converted to ctDNA positivity progressed; ctDNA clearance was linked to favorable outcomes.\"}]","Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers | PDF",1790092465,23]